Systemic sclerosis – a team approach By Dr Janet Roddy, Rheumatologist, Shenton Park Systemic sclerosis, (scleroderma) is a multi-system, heterogeneous condition. The clinical manifestations are a result of vascular system and fibroblast pathology. Most existing therapies are vasoactive or immunomodulatory. There are recognised associations between anti-centromere antibodies (ACA) and limited disease, anti-Scl-70 (anti-topo 1) with diffuse disease plus interstitial lung disease, anti-RNA polymerase III (RNAPIII) with diffuse disease plus renal cell crisis. Anti-PM/ Scl is associated with myositis/ scleroderma overlap. Correlations, such as the increased cancer risk seen in anti-RNA PMIII positive patients may be helpful clinically. Raynaud’s disease present in up to 90% of scleroderma patients,
Key messages
Scleroderma is a heterogeneous disease.
Careful monitoring and early treatment may prevent organ damage resulting in reduced morbidity and mortality. Therapy is geared to the organ involved with early immunosuppression in rapidly progressive diffuse disease.
is often refractory to Nifedipine and may be complicated by digital ulcers. Therapy with PDE5 inhibitors (sildenafil or tadalafil) and intravenous iloprost is often required. Bosentan, an endothelial receptor antagonist (ERA), may prevent recurrence of severe digital ulcers.
Very few patients with isolated Raynaud’s develop scleroderma, but look for finger pulp pitting, abnormal nailfold capillaries or scleroderma antibodies. Skin thickening, the hallmark of systemic sclerosis, begins distally often with puffy fingers and progresses proximally. Skin thickening reaching above the elbows and knees defines diffuse disease. These patients are at risk of internal organ involvement especially during the first three to five years. Pulmonary arterial hypertension may occur at any time, often in patients with limited scleroderma. Home blood pressure monitoring may detect an early scleroderma renal crisis. Rapid introduction of ACE inhibitor therapy markedly improves outcome in this medical emergency.
Has your patient been injured at work or in a motor vehicle accident ? Guardian Exercise Rehabilitation has 20 years’ experience in rehabilitation interventions. Guardian Exercise Rehabilitation’s allied health clinicians provide treatment and prescription of therapeutic exercise-based programs for individuals afflicted with injury or illness, principally under a compensable-injury policy.
Experienced team of mobile Physiotherapists and Exercise Physiologists Industry leaders in clinical exercise interventions Outcomes focused with self-efficacy for clients Video consultations for remote patients throughout WA Our clinicians consult clients across a broad spectrum of injuries and illnesses, with significant experience in both musculoskeletal injuries and mental illnesses. We consult clients throughout their recovery journey, from early intervention through to chronicity management. We adopt a biopsychosocial approach with emphasis on collaboration, education and empowerment. Our programs optimise function and healthy re-engagement in work, as well as everyday and recreational activities. Referring to Guardian Exercise Rehabilitation will ensure your patient receives the most appropriate treatment required for the stage and complexity of their injury or condition. E-Refer now at guardianexercise.com.au
T. 1800 001 066 F. 1800 001 077
40 | OCTOBER 2020
E. admin@guardianexercise.com.au
Mobile services: Physiotherapy | Exercise Physiology
MEDICAL FORUM | MUSCULOSKELETAL ISSUE
BACK TO CONTENTS
CLINICAL UPDATE
